Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Rhea-AI Summary

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) has completed a share capital reduction by decreasing the nominal value of its shares from €1.00 to €0.01. This change, approved by shareholders at the 2024 AGM, aims to:

• Improve the company's ability to attract new financing
• Pursue M&A activities
• Enhance incentives for management and employees through equity awards
• Improve the company's equity composition

The number of ordinary shares remains unchanged at 26,066,809. The €0.99 per share reduction has been added to the company's distributable reserves. Updated articles of association are now available on Vivoryon's website.

Positive

• Improved financial flexibility for attracting new investments
• Enhanced ability to pursue mergers and acquisitions
• Increased capacity to incentivize management and employees
• Strengthened equity composition

Negative

• None.

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Halle (Saale) / Munich, Germany, September 5, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it has completed the reduction of its share capital by decreasing the nominal value of the shares in the Company’s capital to EUR 0.01 from EUR 1.00.

The proposal of the Company’s Board of Directors to amend the Company’s articles of association by, among other items, decreasing the nominal value of the shares in the capital of the Company to EUR 0.01 from EUR 1.00 was approved by the shareholders at the 2024 annual general meeting (AGM), held on June 21, 2024. Following the completion of the creditor opposition procedure in accordance with Dutch law, with no objection having been filed, the Company has now implemented the share capital reduction.

The purpose of the reduction in nominal value is to improve the Company’s capability to attract new financing, pursue M&A activities and incentivize management, members of the Board and employees of the Company through granting equity awards, and also improve the Company's equity composition, as set out in the Company’s notice of annual general meeting published May 8, 2024.

The nominal value of the shares in the Company is now EUR 0.01 each. The number of ordinary shares of the Company in issue (included shares held in treasury) has not changed and consists of 26,066,809 ordinary shares. The amount of the capital reduction (being: EUR 0.99 per share that formed part of the Company’s issued share capital) has been added to the Company’s distributable reserves. The Company’s updated articles of association have been posted on the Company’s website.

###

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com.

Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com

Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu

Attachment

• 2024-09-05_VVY Share capital reduction

FAQ

What is the new nominal value of Vivoryon Therapeutics (VVY) shares after the capital reduction?

The new nominal value of Vivoryon Therapeutics (VVY) shares after the capital reduction is €0.01, decreased from €1.00.

How many ordinary shares does Vivoryon Therapeutics (VVY) have after the share capital reduction?

Vivoryon Therapeutics (VVY) still has 26,066,809 ordinary shares after the share capital reduction. The number of shares has not changed.

What are the main purposes of Vivoryon Therapeutics' (VVY) share capital reduction in 2024?

The main purposes are to improve the company's ability to attract new financing, pursue M&A activities, incentivize management and employees through equity awards, and improve the company's equity composition.

When was the share capital reduction of Vivoryon Therapeutics (VVY) approved by shareholders?

The share capital reduction of Vivoryon Therapeutics (VVY) was approved by shareholders at the annual general meeting (AGM) held on June 21, 2024.